Protecting against wayward human induced pluripotent stem cells with a suicide gene

• Published in: Biomaterials 2012-04, Vol.33 (11), p.3195-3204
• Main Authors: Cheng, Fuyi, Ke, Qiong, Chen, Fei, Cai, Bing, Gao, Yong, Ye, Chenghui, Wang, Ding, Zhang, Li, Lahn, Bruce T, Li, Weiqiang, Xiang, Andy Peng
• Format: Article
• Language: English
• Subjects: Advanced Basic Science; Animals; Apoptosis - genetics; Cell Survival - genetics; Cell Transformation, Neoplastic - genetics; Cell Transformation, Neoplastic - pathology; Cells, Cultured; Dentistry; Embryonic Stem Cells - cytology; Embryonic Stem Cells - physiology; Genes, Transgenic, Suicide - genetics; Genetic Enhancement - methods; Homeodomain Proteins - genetics; Human induced pluripotent stem cells; Humans; Mice; Mice, SCID; Nanog; Nanog Homeobox Protein; Suicide gene; Thymidine kinase; Thymidine Kinase - genetics
• ISSN: 0142-9612; 1878-5905
• DOI: 10.1016/j.biomaterials.2012.01.023

Abstract The generation of human induced pluripotent stem cells (hiPSCs) opens a prospect for regenerative medicine. However, transplantation of somatic cells derived from hiPSCs still harbor many risks such as cells’ incorrect differentiation or over-proliferation, and the worst, tumor formation. Therefore, it’s essential to ravel out these obstacles before their clinical application. Herein, we genetically modified hiPSCs and human embryonic stem cells (hESCs) with a truncated herpes simplex virus delta thymidine kinase (deltaTK) gene driven by EF1α or Nanog promoter to selectively ablate wayward pluripotent stem cells. The results showed that insertion of deltaTK gene did not alter their pluripotency and self-renewal capacity but rendered them sensitive to ganciclovir, which induced elimination of deltaTK+ cells in vitro in a dose and time-dependent manner, most importantly, facilitated both prevention and ablation of tumors in vivo. Furthermore, comparative analysis between transduced hiPSCs and hESCs showed that there was no difference in ganciclovir sensitivity between them. This approach may help to develop safety strategies for clinical application of hiPSCs in regenerative medicine in the future.